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Abstract
Prostate cancer remains the most common malignancy among men and the second leading cause of male
cancer-related mortality. Death from this disease is invariably due to resistance to androgen deprivation therapy.
Our improved understanding of the biology of prostate cancer has heralded a new era in molecular anticancer
drug development, with multiple novel anticancer drugs for castration resistant prostate cancer now entering the
clinic. These include the taxane cabazitaxel, the vaccine sipuleucel-T, the CYP17 inhibitor abiraterone, the novel
androgen receptor antagonist MDV-3100 and the radionuclide alpharadin. The management and therapeutic
landscape of prostate cancer has now been transformed with this growing armamentarium of effective antitumor
agents. This review discusses strategies for the prevention and personalization of prostate cancer therapy, with a
focus on the development of predictive and intermediate endpoint biomarkers, as well as novel clinical trial
designs that will be crucial for the optimal development of such anticancer therapeutics.
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Introduction
Prostate cancer is the leading malignancy among males
and the second most common cause of male cancer-
related deaths after lung cancer [1]. Although the dis-
ease is potentially curable with local therapy when con-
fined to the prostate gland, approximately 33% of
patients develop resistance to local treatments and even-
tually progress to have incurable metastatic disease.
Mortality from this disease is usually due to resistance
to androgen deprivation therapy and the eventual devel-
opment of castration resistant prostate cancer (CPRC).
The molecular etiology of the development of resistance
to prostate cancer therapies is still not fully understood,
with previous and ongoing studies hindered by inade-
quate preclinical models and issues in acquiring prostate
tumor tissue [2].
Novel strategies in castration resistant prostate
cancer
Strategies developed to counteract androgen-deprivation
therapy resistance have had only modest clinical benefit.
Indeed, prior to 2010, only docetaxel chemotherapy
improved overall survival in patients with CRPC com-
pared with mitoxantrone [3]. However, with recent
developments in novel chemotherapeutics and targeted
agents, there appears to be a new dawn in the manage-
ment of prostate cancer, with a number of novel antic-
ancer drugs for CRPC recently entering the clinic. The
key antitumor agents that have shown greatest promise
include the novel taxane cabazitaxel (Jevtana,S a n o f i -
Aventis) [4], the vaccine sipuleucel-T (Provenge; Den-
dreon) [5], the CYP17 inhibitor abiraterone (Zytiga;
Ortho Biotech) [6], the novel androgen-receptor antago-
nist MDV-3100 (Medivation/Astellas) [7] and the radioi-
sotope alpharadin (radium 223; Algeta/Bayer Pharma
AG) (Table 1) [3].
It is therefore now critical that these novel agents are
appropriately applied to the CRPC treatment pathway to
maximize benefit for patients suffering from advanced-
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cost. Thus, the discovery of biomarkers and diagnostics
for prostate cancer screening, as well as the develop-
ment of predictive and intermediate endpoint biomar-
kers and novel clinical trial designs will be crucial for
the optimization of novel molecularly targeted therapeu-
tics in CRPC [3].
This review discusses strategies for the prevention and
personalization of prostate cancer therapy, with a focus
on the development of predictive and intermediate end-
point biomarkers, as well as novel clinical trial designs
that will be crucial for the optimal development of such
anticancer therapeutics.
Screening strategies in prostate cancer
The detection rate and incidence of prostate cancer has
risen in recent decades partly because of the increased
u s eo fp r o s t a t es p e c i f i ca n t i g e n( P S A )a sas c r e e n i n g
tool [8]. This has led to an increased pick up rate in
localized prostate cancers, most of which comprise low
grade and low volume prostate tumors. Historically,
autopsy studies have shown that incidental prostate can-
cer is relatively common, especially in older males.
Thompson and colleagues estimated the prevalence of
prostate cancer in males aged between 55 and 70 years
to be approximately 6% and following 7 years of surveil-
lance, prostate cancer was diagnosed in 24% of males in
the control arm, and 18% of males in the treatment arm
[9]. Whilst all prostate cancers will inevitably progress,
many do so at relatively slow rates and never actually
lead to clinically significant consequences. As such, the
risk-benefit balance in the early detection and interven-
tion of prostate cancer hast ob ec o n s i d e r e di ns u c h
patients. The risks of peri-operative complications, long
term issues such as urinary incontinence and impotence
need to be considered. In contrast, males with aggressive
prostate malignancies will benefit from an active surveil-
lance approach. As a result of this great variation in the
potential aggressiveness of prostate cancer and the non-
cancer specific nature of PSA, great debate has ensued
on the appropriateness of PSA screening.
Prostate cancer screening trials
Two recent large randomized clinical trials published in
the New England Journal of Medicine on prostate can-
cer screening demonstrated that prostate cancer related
deaths are relatively infrequent during the first 10 years
following screen detection and that up to 48 males have
to be identified in order to prevent a single prostate
cancer death [10,11]. While the U.S. trial showed no
benefit in mortality from screening, the European study
demonstrated that a small decline in prostate cancer
mortality with large numbers of subjects required to
receive aggressive treatments to benefit a relative few.
Significantly, it has been estimated that up to US$5.2
million would need to be spent on screening and inter-
ventions, to prevent a single prostate cancer-related
death.
U.S. Preventative Services Task Force guidelines
Following these data and evidence from other key clini-
cal trials, the U.S. Preventative Services Task Force
Table 1 Key clinical trials in castration resistant prostate cancer.
Agent Phase No. of patients PSA RR
>50%
Median OS
(months)
Median
PFS
(months)
Comments
Prednisone + docetaxel vs
docetaxel vs mitoxantrone +
prednisone
III 1,006 (CT-naive) 45% vs 48%
vs 32%
18.9 vs 17.4 vs
16.5
NA Docetaxel approved as first line
therapy for CRPC
Sipuleucel-T vs placebo III 512 (CT-naive) 2.6% vs 1.3% 25.8 vs 21.7 3.7 vs 3.6
(TTrP)
Sipuleucel-T approved for CT-naive
patients with asymptomatic or mildly
symptomatic CRPC
Prednisone + abiraterone vs
prednisone + placebo
III 1,195 (post-CT) 29.1% vs
5.5%
14.8 vs 10.9 5.6 vs 3.6 Abiraterone approved for post-
docetaxel setting
Prednisone + cabazitaxel vs
prednisone + mitoxantrone
III 755 (post-CT) 39.2% vs
17.8%
(overall PSA
RR)
15.1 vs 12.7 2.8 vs 1.4 Cabazitaxel new standard second line
chemotherapy
MDV3100 vs placebo III 1199 (Interim
analysis triggered
at 520 events)
NA 18.4 vs 13.6 (37%
reduction in risk
of death)
NA Interim analysis
Alpharadin vs placebo III 922 NA 14 vs 11.2 NA Interim analysis
Prior to 2010, only docetaxel chemotherapy demonstrated a survival benefit in patients with CRPC compared with mitoxantrone. Since then, sipuleucel-T,
abiraterone, cabazitaxel, MDV3100 and alpharadin have met their respective primary endpoints in phase III clinical trials. These novel agents have now obtained
regulatory approval, or are expected to be approved in due course
CRPC castration-resistant prostate cancer; CT chemotherapy, NA not available; OS overall survival; PFS progression-free survival; PSA prostate-specific antigen; RR
response rate; TTP time to progression; TTrP time to radiological progression
Yap et al. The EPMA Journal 2012, 3:3
http://www.epmajournal.com/content/3/1/3
Page 2 of 6(USPSTF) recently released guidelines advising against
PSA-based screening for prostate cancer in asympto-
matic men [12]. The USPSTF acknowledged that there
are data supporting the detection of many cases of
asymptomatic prostate cancer through PSA-based
screening. Although the majority of such PSA-screen
detected asymptomatic individuals have a tumor that
meets histological criteria for prostate cancer, the tumor
will either not progress or is so indolent, it will not
impact mortality. In view of this, better biomarkers and
novel diagnostics are clearly required for the detection
of potentially aggressive prostate cancer.
A new era in CRPC antitumor therapeutics
Our improved understanding of the underlying biology
of CRPC has heralded a new era in molecular anticancer
drug development, with a number of novel anticancer
drugs for CRPC recently entering the clinic (Table 1). It
is thus now critical that agents such as abiraterone [6],
MDV-3100 [7], cabazitaxel [4], sipuleucel-T [5], and
alpharadin [3] are appropriately applied to the CRPC
treatment pathway to maximize benefits for patients suf-
fering from CRPC. Thus, the development of predictive
and intermediate endpoint biomarkers, and the incor-
poration of novel clinical trial designs are crucial for the
optimal development of such anticancer targeted thera-
pies [3].
Predictive biomarkers in prostate cancer
The rational selection of appropriate populations of
patients for molecular therapeutics is important in a
heterogeneous disease like CRPC, in order to fine tune
antitumor responses to selective targeted therapeutics.
We envision that the use of predictive and enrichment
biomarkers will be essential to the optimal development
of targeted therapeutics. An often cited example is
tumoral TMPRSS2-ETS gene fusion in CRPC, which
may, in the future, prove to predict for antitumor
responses to novel agents, such as abiraterone [13].
TMPRSS2-ETS gene fusion in CRPC
The ERG gene has been observed to be one of the most
commonly overexpressed proto-oncogenes in prostate
cancer and present in approximately 72% of cases of
prostate cancer [14]. Tomlins and colleagues demon-
strated that TMPRSS2, a serine protease secreted by
prostate epithelial cells in response to androgen expo-
sure, is fused to ERG, a member of the ETS family of
oncogenes [15]. This rearrangement results in the crea-
tion of a fusion transcript called TMPRSS2-ETS. This
leads to the overexpression of the ETS oncogene, initi-
ally under androgen and the androgen receptor (AR)
control, although androgen dependence may be even-
tually lost in advanced disease. It now appears that the
activation of this pathway may be central to prostate
oncogenesis [16,17]. Recent clinical studies assessing
abiraterone have indicated that the presence of an ERG
rearrangement was associated with the magnitude of
PSA decline following abiraterone treatment (P = 0.007)
[13]. This association is now being evaluated prospec-
tively in phase III CPRC clinical trials and results are
eagerly anticipated.
Intermediate endpoint biomarkers in prostate
cancer
Another major issue that needs to be urgently addressed
for the personalization of prostate cancer is the discov-
ery and development of analytically validated and clini-
cally qualified intermediate endpoint or surrogate
biomarkers of clinical benefit [3].
Urgent need for qualified intermediate endpoint
biomarkers in CRPC
Several aspects of the clinical behavior of prostate can-
cer beggar the need for intermediate endpoint biomar-
kers in late phase clinical trials. Firstly, the
measurement of the primary tumor within the prostate
can be inaccurate with conventional imaging modalities.
In addition, prostate cancer frequently results in bone
metastases, rather than visceral disease that may be
easily and accurately measured using conventional radi-
ological methods. In contrast, bony disease is difficult to
quantify and the assessment of existing lesions on bone
scans is unreliable.
Although a proportion of patients do have measurable
disease, and while trials may indeed be limited to this
patient population, the presence of measurable visceral
disease is usually associated with a more aggressive phe-
notype and therefore worse prognosis. Therefore, select-
ing patients with measurable disease for these trials may
lead to biased patient selection and restrict the extrapo-
lation of the trial data to the general prostate cancer
population. Tumor measurements are therefore difficult
to utilize as a predictor of clinical benefit in clinical
trials of this disease.
PSA is not a validated intermediate endpoint biomarker
PSA is not specific to prostate cancer and may be pre-
sent in million-fold higher concentrations in prostatic
secretions, with PSA leakage potentially altering mea-
sured levels in patients. In addition, it is now accepted
that PSA gene expression is due to AR transcriptional
activity, and therefore altered AR transcription could
lead to declines in PSA levels, but not in the desired
reduction in tumor growth.
While PSA progression has been shown to be signifi-
cantly associated with survival, changes in PSA are not
robust intermediate endpoint biomarkers of survival.
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of three-weekly or weekly docetaxel, both with predni-
sone, versus mitoxantrone and prednisone in patients
with advanced CRPC [18]. This study demonstrated a
survival advantage for 3-weekly docetaxel over mitoxan-
trone (p < 0.01), with no significant survival advantage
for the weekly docetaxel arm. However, both docetaxel
schedules resulted in similar rates of PSA decrement
rates (45% and 48% of patients had a PSA fall >50% on
the 3-weekly and weekly schedules respectively, versus
32% on the mitoxantrone arm). Based on these data, it
was concluded that PSA declines by >50% are not a sur-
rogate biomarker for overall survival or patient benefit.
Retrospective analyses of data from several rando-
mized clinical trials with the anti-androgen bicalutamide
also report that PSA is not a valid intermediate endpoint
biomarker in advanced prostate cancer [19]. These data
indicate that overall survival and quality of life remain
the optimal approvable primary endpoints for such stu-
dies [20]. For patients with progressive prostate cancer
and castrate levels of testosterone, the Prostate Cancer
Clinical Trials Working Group (PCWG2) recommends
an increased emphasis on time-to-event endpoints, such
as failure to progress, as decision aids in moving from
phase II to III clinical trials [21].
It is important to note that progression-free survival
(PFS) is a poor intermediate endpoint of overall survival
in prostate cancer, with overall associations between
PFS and overall survival at best moderate (0.4 for radio-
graphic PFS and 0.33 for PSA PFS) [21].
Clinical trial endpoints in prostate cancer
Due to the necessity to measure overall survival as a pri-
mary endpoint, Phase III clinical trials evaluating novel
drugs in prostate cancer have traditionally involved large
p a t i e n tc o h o r t sa n da ne x t e n d e dp e r i o do ff o l l o w - u p .
This has led to delays in the analysis and reporting of
trial data and the availability of level I evidence that
could potentially improve patient care. Replacing overall
survival (true endpoint) with an intermediate endpoint
that accurately reflects the benefit of new treatments
may potentially accelerate drug development [22]. Such
surrogate biomarkers could be assessed earlier and more
frequently to accelerate treatment advances. This neces-
sity to expedite oncological drug development is
reflected by changes in cancer drug approval regulations.
These regulations now allow accelerated approval when
clinical trials establish that the new antitumor agent has
an effect on a surrogate endpoint that is “reasonably
likely” to predict clinical benefit on the basis of an effect
on an endpoint other than survival.
These regulatory changes reflect increasing public
pressure for the rapid approval of promising new mole-
cularly targeted therapies generated by our burgeoning
knowledge of the molecular biology of prostate cancer.
The urgent need to develop novel endpoints for prostate
cancer trials led the US Food and Drug Administration
to conduct a public workshop in 2004 on clinical trial
endpoints in prostate cancer. At this workshop, end-
points regarded as acceptable for the regulatory approval
of new drugs in prostate cancer were discussed [23].
These discussions indicated that novel validated biomar-
kers, established as “true” surrogates of clinical benefit,
are urgently needed for the management of patients
with advanced prostate cancer.
With several antitumor agents recently approved for
use in CRPC and numerous others in late phase clinical
trials, it is likely to be increasingly more difficult to
demonstrate a survival benefit for future drugs since
crossover to an effective treatment may confound an
overall survival effect [3,24]. This may lead to larger,
more costly and protracted studies [3]. There is thus an
urgent unmet need in CRPC for an intermediate end-
point biomarker for survival, especially since conven-
tional methods, e.g. bone scan changes are difficult to
interpret and changes in PSA levels are not surrogates
for survival [21].
Since the measurement of PSA levels is not a validated
surrogate biomarker of antitumor response, there is an
urgent need for the development of novel intermediate
endpoint biomarkers; this may potentially include the
enumeration of circulating tumor cells (CTCs).
Personalizing prostate cancer treatments with
circulating tumor cells
Changes in CTC counts from baseline during treatment
are now recognized as a prognostic marker in patients
with metastatic breast, prostate and colorectal cancer
[25-27]. This validated enumeration is feasible due to
advances in technology that allow the automated and
high-throughput separation, visualisation and quantita-
tion of cancer cells from blood [28]. The study of CTC
with the CellTracks
® system (Immunicon, PA), allows
highly reproducible (85-95% reproducibility between
laboratories) enumeration of CTCs [28]. CTCs are not
detected in healthy subjects or in patients with non-
malignant diseases. Although CTC counts are of prog-
nostic relevance, CTC enumeration has not been vali-
dated as a surrogate of clinical benefit.
The ability to longitudinally evaluate gene amplifica-
tions, mutations, deletions or translocations that have
crucial roles in CRPC pathogenesis with CTCs provides
unique insights into the underlying and evolving biology
of the tumor, without the necessity for invasive biopsies
[29]. This will also allow the analysis of molecular
changes that occur secondary to treatment pressures
and intra-patient tumor heterogeneity that may other-
wise have been missed with tumor biopsies [29]. It also
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profiles of risk, prognosis and likely response.
CTC enumeration as an intermediate endpoint biomarker
Highly significant differences in survival based on
changes in CTC counts following cytotoxic and hor-
mone therapy have been observed. The IMMC38 trial
evaluated the impact of cytotoxic chemotherapy on
CTCs and PSA in patients with CRPC. Significantly, the
fold change of CTCs at 4, 8 and 12 weeks following
treatment was the most important prognostic factor in
multivariate analyses (p < 0.0001), suggesting that CTC
count declines were able to identify patients likely to
benefit from cytotoxic chemotherapy [13,26,30,31]. In
contrast, PSA declines added little benefit to the perfor-
mance of the receiver-operator curve. These data have
now been validated prospectively in the randomized
Phase III abiraterone trial [6] where CTC count declines
at 4, 8 and 12 weeks after starting therapy met the sta-
tistical requirements for surrogacy of overall survival
[32]. These CTC analyses in almost 1,000 patients
demonstrated that both CTC baseline values were highly
concordant (r = 0.83) and CTC declines and conversion
(from CTC ≥ 5 to < 5) were strongly prognostic as early
as 4 weeks after treatment, with abiraterone resulting in
a highly significant increased likelihood of falling CTC
counts. In addition, the introduction of CTC count
declines into a multivariate prognostic model reduced
the treatment effect significantly (HR: 0.74 to 0.97), indi-
cating that CTC count declines explained much of the
treatment effect on survival and meet stringent surro-
gacy criteria [32].
Clinical trial designs in CRPC
Designing clinical trials for CRPC remains challenging
because of a number reasons; the standard criteria for
measuring radiological responses - Response Evaluation
Criteria In Solid Tumors (RECIST) - is not always
applicable because measurable disease occurs infre-
quently in patients with CRPC. In addition, the natural
history of this disease may potentially be sustained over
decades because of the slow rate of growth of certain
prostate cancers and finally because the target popula-
tion is mainly elderly and possibly more fragile and sen-
sitive to treatment-related toxicities. Thus, the design of
clinical trials in CRPC is a constantly evolving paradigm,
especially with the development of novel anticancer
therapies, including both molecularly targeted drugs and
immunotherapies.
Prostate Cancer Clinical Trials Working Group guidelines
In 2008, a committee of investigators defined new con-
sensus criteria to plan and conduct trials for prostate
cancer [21]. The PCWG2 developed guidelines to
conduct clinical trials for patients with CRPC, standar-
dizing trial endpoints for agents that act through diverse
mechanisms. The PCWG2 distinguished two types of
study efficacy objectives: the control, relief, or elimina-
tion of disease manifestations (e.g. pain) that are present
when treatment is initiated, and the prevention or delay
of disease manifestations (e.g. death) expected to occur.
The PCWG2 recommended an increased emphasis on
time-to-event endpoints (i.e. failure to progress) as deci-
sion aids in proceeding from phase II to phase III trials,
as well as the reporting of outcomes independently for
PSA, imaging, and clinical measures, avoiding grouped
categorizations such as complete or partial response.
Early changes in PSA and/or pain should not be acted
on without other evidence of disease progression, and
treatment should be continued for at least 3 months to
ensure adequate drug exposure. Bone scans should be
reported as “new lesions” or “no new lesions,” changes
in soft-tissue disease assessed by RECIST, and pain
using validated scales. These PCWG2 recommendations
are due to evolve as data are generated on the utility of
intermediate end points to predict clinical benefit.
Adaptive clinical trial strategies
In view of the unique features of CRPC, customized,
adaptive, hypothesis-testing trial designs should be con-
sidered in future clinical trials. Such studies may permit
the alteration of the randomization rate during a trial in
real time to increase the chance that a patient is allo-
cated to the best treatment. Adaptive trial strategies per-
mit the statistical model to learn as the study progresses
through interim assessments by adapting sample size or
discontinuing the trial early for success, futility or harm.
Also, such studies may allow the switching of hypothesis
of non-inferiority to superiority or vice-versa, or drop-
ping of selected arms or doses. Recent examples of clini-
cal studies using an adaptive strategy are the BATTLE
trial in non-small cell lung cancer [33] and I-SPY2 study
[34] in locally advanced breast cancer.
Future outlook and conclusions
The management and therapeutic landscape of prostate
cancer is clearly changing with the recent approval of a
range of effective antitumor agents. With the armamen-
tarium of drugs available for routine use in advanced
prostate cancer, it is critical that they are now applied
appropriately in order to maximize patient benefit and
minimize costs. Potential issues including drug-related
toxicities and cross-resistance to individual agents after
exposure to a prior treatment should be considered. In
the future, it is likely that transition from one treatment
regimen to the next should be based on a combination
of clinical, biochemical and radiological factors. Impor-
tantly, novel biomarker assays, such as validated
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need to be routinely incorporated into treatment path-
ways in the future. Much work also needs to be contin-
ued in the future for the development of robust
diagnostics for prostate cancer screening.
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